Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum

Jason M. Wooden, Leland Hartwell, Brandi Vasquez, Carol Hopkins Sibley

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Pyrimethamine and cycloguanil are competitive inhibitors of the Plasmodium enzyme dihydrofolate reductase (DHFR). They have been effective treatments for malaria, but rapid selection of populations of the parasite resistant to these drugs has compromised their effectiveness. Parasites resistant to either drug usually have point mutations in the dhfr gene, but the frequency of these mutations is unknown. To study drug resistance more effectively, we transferred the DHFR domain of the dhfr-thymidylate synthase gene from a drug-sensitive line of P. falciparum to a strain of the budding yeast, Saccharomyces cerevisiae, that lacks endogenous DHFR activity. Expression of the P. falciparum dhfr is controlled by the yeast dhfr 5' and 3' regulatory regions and the heterologous enzyme provided all of the functions of the yeast dhfr gene. These yeast were susceptible to pyrimethamine and cycloguanil at low concentrations that inhibit P. falciparum (IC50 about 10-8 and 10-7 M, respectively). Yeast expressing constructs with dhfr alleles from pyrimethamine-resistant strains were resistant to both pyrimethamine and cycloguanil (IC50 > 10-6 M); resistance of the yeast depended on the dhfr allele they expressed. The experimental drug WR99210 efficiently killed all three yeast strains (IC50 about 10-8 M) but the pyr(R) strains showed collateral hypersensitivity to drug. The yeast transformants carrying the drug-sensitive allele can now be screened quickly and quantitatively to identify new drugs or combinations of drugs and determine which drugs select resistant parasites least efficiently. Such compounds would be excellent candidates for development of treatments with a longer life in clinical practice.

Original languageEnglish (US)
Pages (from-to)25-40
Number of pages16
JournalMolecular and Biochemical Parasitology
Volume85
Issue number1
DOIs
StatePublished - Mar 1997
Externally publishedYes

Fingerprint

Tetrahydrofolate Dehydrogenase
Plasmodium falciparum
Yeasts
Pyrimethamine
Pharmaceutical Preparations
Inhibitory Concentration 50
Parasites
Alleles
Drug Hypersensitivity
Thymidylate Synthase
Saccharomycetales
Plasmodium
Nucleic Acid Regulatory Sequences
Enzyme Inhibitors
Drug Combinations
Point Mutation
Drug Resistance
Gene Frequency
Genes
Malaria

Keywords

  • antifolate
  • drug resistance
  • malaria
  • Plasmodium falciparum
  • Saccharomyces cerevisiae

ASJC Scopus subject areas

  • Molecular Biology
  • Parasitology

Cite this

Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. / Wooden, Jason M.; Hartwell, Leland; Vasquez, Brandi; Sibley, Carol Hopkins.

In: Molecular and Biochemical Parasitology, Vol. 85, No. 1, 03.1997, p. 25-40.

Research output: Contribution to journalArticle

@article{ae4ae32476734185bc2e534128b3d0b9,
title = "Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum",
abstract = "Pyrimethamine and cycloguanil are competitive inhibitors of the Plasmodium enzyme dihydrofolate reductase (DHFR). They have been effective treatments for malaria, but rapid selection of populations of the parasite resistant to these drugs has compromised their effectiveness. Parasites resistant to either drug usually have point mutations in the dhfr gene, but the frequency of these mutations is unknown. To study drug resistance more effectively, we transferred the DHFR domain of the dhfr-thymidylate synthase gene from a drug-sensitive line of P. falciparum to a strain of the budding yeast, Saccharomyces cerevisiae, that lacks endogenous DHFR activity. Expression of the P. falciparum dhfr is controlled by the yeast dhfr 5' and 3' regulatory regions and the heterologous enzyme provided all of the functions of the yeast dhfr gene. These yeast were susceptible to pyrimethamine and cycloguanil at low concentrations that inhibit P. falciparum (IC50 about 10-8 and 10-7 M, respectively). Yeast expressing constructs with dhfr alleles from pyrimethamine-resistant strains were resistant to both pyrimethamine and cycloguanil (IC50 > 10-6 M); resistance of the yeast depended on the dhfr allele they expressed. The experimental drug WR99210 efficiently killed all three yeast strains (IC50 about 10-8 M) but the pyr(R) strains showed collateral hypersensitivity to drug. The yeast transformants carrying the drug-sensitive allele can now be screened quickly and quantitatively to identify new drugs or combinations of drugs and determine which drugs select resistant parasites least efficiently. Such compounds would be excellent candidates for development of treatments with a longer life in clinical practice.",
keywords = "antifolate, drug resistance, malaria, Plasmodium falciparum, Saccharomyces cerevisiae",
author = "Wooden, {Jason M.} and Leland Hartwell and Brandi Vasquez and Sibley, {Carol Hopkins}",
year = "1997",
month = "3",
doi = "10.1016/S0166-6851(96)02808-3",
language = "English (US)",
volume = "85",
pages = "25--40",
journal = "Molecular and Biochemical Parasitology",
issn = "0166-6851",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum

AU - Wooden, Jason M.

AU - Hartwell, Leland

AU - Vasquez, Brandi

AU - Sibley, Carol Hopkins

PY - 1997/3

Y1 - 1997/3

N2 - Pyrimethamine and cycloguanil are competitive inhibitors of the Plasmodium enzyme dihydrofolate reductase (DHFR). They have been effective treatments for malaria, but rapid selection of populations of the parasite resistant to these drugs has compromised their effectiveness. Parasites resistant to either drug usually have point mutations in the dhfr gene, but the frequency of these mutations is unknown. To study drug resistance more effectively, we transferred the DHFR domain of the dhfr-thymidylate synthase gene from a drug-sensitive line of P. falciparum to a strain of the budding yeast, Saccharomyces cerevisiae, that lacks endogenous DHFR activity. Expression of the P. falciparum dhfr is controlled by the yeast dhfr 5' and 3' regulatory regions and the heterologous enzyme provided all of the functions of the yeast dhfr gene. These yeast were susceptible to pyrimethamine and cycloguanil at low concentrations that inhibit P. falciparum (IC50 about 10-8 and 10-7 M, respectively). Yeast expressing constructs with dhfr alleles from pyrimethamine-resistant strains were resistant to both pyrimethamine and cycloguanil (IC50 > 10-6 M); resistance of the yeast depended on the dhfr allele they expressed. The experimental drug WR99210 efficiently killed all three yeast strains (IC50 about 10-8 M) but the pyr(R) strains showed collateral hypersensitivity to drug. The yeast transformants carrying the drug-sensitive allele can now be screened quickly and quantitatively to identify new drugs or combinations of drugs and determine which drugs select resistant parasites least efficiently. Such compounds would be excellent candidates for development of treatments with a longer life in clinical practice.

AB - Pyrimethamine and cycloguanil are competitive inhibitors of the Plasmodium enzyme dihydrofolate reductase (DHFR). They have been effective treatments for malaria, but rapid selection of populations of the parasite resistant to these drugs has compromised their effectiveness. Parasites resistant to either drug usually have point mutations in the dhfr gene, but the frequency of these mutations is unknown. To study drug resistance more effectively, we transferred the DHFR domain of the dhfr-thymidylate synthase gene from a drug-sensitive line of P. falciparum to a strain of the budding yeast, Saccharomyces cerevisiae, that lacks endogenous DHFR activity. Expression of the P. falciparum dhfr is controlled by the yeast dhfr 5' and 3' regulatory regions and the heterologous enzyme provided all of the functions of the yeast dhfr gene. These yeast were susceptible to pyrimethamine and cycloguanil at low concentrations that inhibit P. falciparum (IC50 about 10-8 and 10-7 M, respectively). Yeast expressing constructs with dhfr alleles from pyrimethamine-resistant strains were resistant to both pyrimethamine and cycloguanil (IC50 > 10-6 M); resistance of the yeast depended on the dhfr allele they expressed. The experimental drug WR99210 efficiently killed all three yeast strains (IC50 about 10-8 M) but the pyr(R) strains showed collateral hypersensitivity to drug. The yeast transformants carrying the drug-sensitive allele can now be screened quickly and quantitatively to identify new drugs or combinations of drugs and determine which drugs select resistant parasites least efficiently. Such compounds would be excellent candidates for development of treatments with a longer life in clinical practice.

KW - antifolate

KW - drug resistance

KW - malaria

KW - Plasmodium falciparum

KW - Saccharomyces cerevisiae

UR - http://www.scopus.com/inward/record.url?scp=0031002773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031002773&partnerID=8YFLogxK

U2 - 10.1016/S0166-6851(96)02808-3

DO - 10.1016/S0166-6851(96)02808-3

M3 - Article

C2 - 9108546

AN - SCOPUS:0031002773

VL - 85

SP - 25

EP - 40

JO - Molecular and Biochemical Parasitology

JF - Molecular and Biochemical Parasitology

SN - 0166-6851

IS - 1

ER -